Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × D2C7-(scdsFv)-PE38KDEL × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 109 Cyclophosphamide 79 fludarabine 59 Carboplatin 59 Injections 58 Bevacizumab 51 Gemcitabine 41 venetoclax 38 Specimen Handling 38 Paclitaxel 38 Nivolumab 38 Magnetic Resonance Spectroscopy 36 Cisplatin 36 Dexamethasone 35 Biopsy 32 Docetaxel 30 atezolizumab 29 Temozolomide 28 toripalimab 24 Irinotecan 24 Fluorouracil 24 Capecitabine 24 Azacitidine 24 abemaciclib 23 Pemetrexed 23 Oxaliplatin 23 Fulvestrant 22 Rituximab 21 fludarabine phosphate 19 Cetuximab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05734560 2025-10-06

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Duke University

Phase 1/2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡